A uremic solute, p-cresol, inhibits the proliferation of endothelial progenitor cells via the p38 pathway

Circulation Journal

Volumn 75, Issue 9, 2011, Pages 2252-2259

  Ying, Yuan ^a   Yang, Ke ^a   Liu, Yan ^a   Chen, Qiu J ^a   Shen, Wei F ^a   Lu, Lin ^a   Zhang, Rui Y ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Endothelial progenitor cell; Indoxyl sulfate; P cresol

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; INDICAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NOTCH1 RECEPTOR; PARA CRESOL;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIAL PROGENITOR CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOSIS INHIBITION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION;

CELL PROLIFERATION; CELLS, CULTURED; CRESOLS; ENDOTHELIAL CELLS; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PHYSIOLOGIC; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PYRIDINES; RECEPTOR, NOTCH1; STEM CELLS; URINE;

EID: 80052170947     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-11-0046     Document Type: Article

References (27)

1. Foley RN. Clinical epidemiology of cardiovascular disease in chronic kidney disease. J Ren Care 2010; 36(Suppl 1): 4-8.
2. Roberts MA, Hare DL, Ratnaike S, Ierino FL. Cardiovascular biomarkers in CKD: Pathophysiology and implications for clinical management of cardiac disease. Am J Kidney Dis 2006; 48: 341-360.
3. Zhu JH, Chen JZ, Wang XX, Xie XD, Sun J, Zhang FR. Homocysteine accelerates senescence and reduces proliferation of endothelial progenitor cells. J Mol Cell Cardiol 2006; 40: 648-652.
4. Scheubel RJ, Kahrstedt S, Weber H, Holtz J, Friedrich I, Borgemann J, et al. Depression of progenitor cell function by advanced glycation endproducts (AGEs): Potential relevance for impaired angiogenesis in advanced age and diabetes. Exp Gerontol 2006; 41: 540-548.
5. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451.
6. Seeger FH, Haendeler J, Walter DH, Rochwalsky U, Reinhold J, Urbich C, et al. p38 mitogen-activated protein kinase downregulates endothelial progenitor cells. Circulation 2005; 111: 1184-1191.
7. Hur J, Yoon CH, Kim HS, Choi JH, Kang HJ, Hwang KK, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arter Throm Vas Bio 2004; 24: 288-293.
8. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1-E7.
9. Gulati R, Jevremovic D, Peterson TE, Chatterjee S, Shah V, Vile RG, et al. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ Res 2003; 93: 1023-1025.
10. Bahlmann FH, De Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103: 921-926.
11. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 2000; 35(4 Suppl 1): S117-S131.
12. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305.
13. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169.
14. Meijers BK, Van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts MF, et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009; 54: 891-901.
15. Liew A, Barry F, O'Brien T. Endothelial progenitor cells: diagnostic and therapeutic considerations. BioEssays 2006; 28: 261-270.
16. Miura M, Numaguchi Y, Ishii M, Kubota R, Takeuchi T, Imamura A, et al. Differentiation capacity of endothelial progenitor cells correlates with endothelial function in healthy young men. Circ J 2009; 73: 1324-1329.
17. Yasu T. Differentiation of endothelial progenitor cells: A useful biomarker? Circ J 2009; 73: 1199-1200.
18. Shumiya T, Shibata R, Shimizu Y, Ishii M, Kubota R, Shintani S, et al. Evidence for the therapeutic potential of ex vivo expanded human endothelial progenitor cells using autologous serum. Circ J 2010; 74: 1006-1013.
19. Jourde-Chiche N, Dou L, Sabatier F, Calaf R, Cerini C, Robert S, et al. Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. J Thromb Haemost 2009; 7: 1576-1584.
20. Brunet P, Dou L, Cerini C, Berland Y. Protein-Bound uremic retention solutes. Adv Ren Replace Ther 2003; 10: 310-320.
21. Kwon SM, Eguchi M, Wada M, Iwami Y, Hozumi K, Iwaguro H, et al. Specific jagged-1 signal from bone marrow microenvironment is required for endothelial progenitor cell development for neovascularization. Circulation 2008; 118: 157-165.
22. Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, et al. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: Implications for modulating arteriogenesis and angiogenesis. Mol Cell Biol 2003; 23: 14-25.
23. Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, Vanholder R. Intradialytic removal of protein-bound uraemic toxins: Role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000; 15: 50-57.
24. Sanaka T, Sugino N, Teraoka S, Ota K. Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 1988; 12: 97-103.
25. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 1997; 62: S23-S28.
26. Ling WH, Hänninen O. Shifting from a conventional diet to an uncooked vegan diet reversibly alters fecal hydrolytic activities in humans. J Nutr 1992; 122: 924-930.
27. Niwa T, Tsukushi S, Ise M, Miyazaki T, Tsubakihara Y, Owada A, et al. Indoxyl sulfate and progression of renal failure: Effects of a low-protein diet and oral sorbent onindoxyl sulfate production in uremic rats and undialyzed uremic patients. Miner Electrolyte Metab 1997; 23: 179-184.